series-a
Stage
About
Excellergy Inc develops first-in-class allergy therapeutics called Effector Cell Response Inhibitors (ECRIs) that rapidly disable the IgE axis by removing IgE from allergic effector cells, neutralizing free IgE, and downregulating receptor expression to control severe allergic diseases.
Explore Excellergy Inc's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.